This work package establishes the project’s governance framework: the coordinator (FSE) oversees day-to-day administration, budget, and legal compliance, and scientific stewardship—organizing meetings, managing contracts, and ensuring that deliverables, milestones, and reports are delivered on time. It also sets up internal communication channels to keep all partners aligned, while implementing a proactive risk-management cycle (identification, analysis, mitigation, control) to address emerging threats. A dynamic Data Management Plan is created and maintained to ensure consistency, accessibility, and integrity of project data across all work packages (WP1-WP10). Finally, the setup of an Advisory Board/ Ethics Committee provides continuous oversight to uphold ethical standards throughout the project lifecycle.

WP4 defines and validates patient eligibility criteria to identify new cohorts who stand to benefit from the modular CAR-T device, leveraging clinical expertise and data analytics to model anticipated outcomes. A comprehensive market and competitor analysis maps current trends, barriers to entry, and growth projections, informing optimal positioning within healthcare systems. Finally, insights from WP2 are used for exploitation and sustainability strategies that outline clear commercialization pathways, partner engagement, and scalable roll-out plans to ensure long-term integration and impact of the innovation.

A PASTEL analysis and expert interviews map out all external influences and key actors to pinpoint the political, economic, social and regulatory factors that will shape technology adoption. It then translates stakeholder insights into prioritized technical and usability requirements via targeted questionnaires, ensuring the device meets real-world needs. Building on this, acceptance studies
systematically gather and analyze stakeholders feedback to establish clear criteria for end-user buy-in, and a comprehensive cost-effectiveness model compares Point-of-Care versus conventional CAR-T therapies (including QALYs, long-term follow-ups, Monte Carlo sensitivity analysis, and workflow-driven cost inputs) to guide strategic decision-making.

WP4 defines and validates patient eligibility criteria to identify new cohorts who stand to benefit from the modular CAR-T device, leveraging clinical expertise and data analytics to model anticipated outcomes. A comprehensive market and competitor analysis maps current trends, barriers to entry, and growth projections, informing optimal positioning within healthcare systems. Finally, insights from WP2 are used for exploitation and sustainability strategies that outline clear commercialization pathways, partner engagement, and scalable roll-out plans to ensure long-term integration and impact of the innovation.

A robust regulatory roadmap is crafted for both the CGT proof-of-concept platform and the modular CAR-T procedure. Early engagement with Notified Bodies and competent authorities ensures that device classification, pre-clinical testing, and evolving regulations are addressed in real time. A detailed European regulatory landscape analysis across EU countries (starting with Germany, Spain) informs consultation with TÜV, PEI, EMA, and other agencies, while comprehensive GMP documentation—including validation plans, risk assessments, and supplier qualification—lays the groundwork for compliant manufacturing in WP6.

Refining and validating the consumable cassette and core instrument to meet GMP specifications for on-site CAR-T production is performed in this working package: partners will iterateon the PoCCGT cassette design (affinity capture, washing, concentration) and verifycell-isolation performance (purity, viability, yield) across multiple donorsamples. Standardized quality-control cartridges and protocols will bedeveloped to automate cell counts, viability checks, and contamination assays, by stakeholder feedback from WP8. Finally, a Digital Twin—built onEclipse BaSyx and FHIR standards—will integrate process and QC data intohospital EHR/LIMS systems, enabling real-time interoperability and streamlinedclinical workflows.

Same-day CAR-T production is established and refined through the comparison of novel vector and gene-editing strategies with classical methods. Both processes are then standardized to ensure consistent, clinical-scale use. It developscutting-edge analytical assays—leveraging CRISPR off-target profiling, 3D ex vivo efficacy screens, and cytokine-release monitoring—to qualify edited cellsfor safety and potency. Finally, it conducts paired comparisons of the new rapid workflow versus traditional ex vivo culture to demonstrate equivalence orsuperiority in product quality.

Simulated onboarding workflows in hospital settings serve to pilot the point-of-care CAR-T platform, while also generating SOPs, training materials, and quality-management documents to assess personnel, infrastructure, and documentation requirements. Guided by insights from WP2 and WP3, this WP then conducts dry runs across partner sites, gathering usability feedback to iteratively refine device deployment and clinical processes while preparing for a Phase 1b trial. Finally, interoperability tests validate data interfaces between the device, Digital Twin, and hospital IT systems, and a clinical study protocol is drafted alongside a comprehensive final report outlining logistics, user insights, and regulatory considerations.

To share EASYGEN’s findings with scientific, clinical, and public audiences the team develops a dynamic dissemination and communication strategy – featuring a unified brand identity, website, social media presence and toolkit for presentations and press releases. It conducts a literature review on CAR-T patient quality of life to inform targeted messaging and convenes roundtable workshops with patient advocacy groups to co-create educational resources and a white paper on lived-experience insights. Ongoing stakeholder networking ensures that healthcare providers and patients are actively engaged throughout the project’s lifespan.

To ensure full compliance withapplicable laws, regulations, and best practices, this working package definesan ethical framework and oversight structure guiding all research and devicedevelopment activities. An Ethics Committee will beconvened to review protocols, informed-consent materials, data-protectionmeasures (e.g., GDPR compliance), and patient-safety procedures, providingguidance and approval at key milestones. Continuous monitoring and reporting mechanismswill be implemented to address any emerging ethical issues throughout theproject lifecycle.